Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)

Corinna Trebst, Sven Jarius, Achim Berthele, Friedemann Paul, Sven Schippling, Brigitte Wildemann, Nadja Borisow, Ingo Kleiter, Orhan Aktas, Tania Kümpfel, Neuromyelitis Optica Study Group (NEMOS), P Albrecht, O Aktas, K Angstwurm, A Berthele, F Bischof, N Borisow, T Böttcher, J Brettschneider, M Buttmann, B Ettrich, J Faiss, A Gass, C Geis, K Guthke, J Havla, H-P Hartung, K Hellwig, B Hemmer, F Hoffmann, U Hofstadtvan Oy, S Jarius, P Kern, C Kleinschnitz, I Kleiter, W Köhler, E Kolesilova, M Krumbholz, T Kümpfel, S Langel, F Lauda, M Liebetrau, R Linker, W Marouf, M Marziniak, I Metz, C Mayer, A Melms, C Münch, O Neuhaus, S Niehaus, F Pache, F Paul, H Pellkofer, R Reuss, A Riedlinger, M Ringelstein, S P Rommer, K Ruprecht, S Schippling, M Schwab, M Stangel, J Stellmann, F Then-Bergh, C Trebst, H Tumani, C Veauthier, K P Wandinger, R Weissert, B Wildemann, C Wilke, A Winkelmann, L Zeltner, C Zentner, U Zettl, U Ziemann, Corinna Trebst, Sven Jarius, Achim Berthele, Friedemann Paul, Sven Schippling, Brigitte Wildemann, Nadja Borisow, Ingo Kleiter, Orhan Aktas, Tania Kümpfel, Neuromyelitis Optica Study Group (NEMOS), P Albrecht, O Aktas, K Angstwurm, A Berthele, F Bischof, N Borisow, T Böttcher, J Brettschneider, M Buttmann, B Ettrich, J Faiss, A Gass, C Geis, K Guthke, J Havla, H-P Hartung, K Hellwig, B Hemmer, F Hoffmann, U Hofstadtvan Oy, S Jarius, P Kern, C Kleinschnitz, I Kleiter, W Köhler, E Kolesilova, M Krumbholz, T Kümpfel, S Langel, F Lauda, M Liebetrau, R Linker, W Marouf, M Marziniak, I Metz, C Mayer, A Melms, C Münch, O Neuhaus, S Niehaus, F Pache, F Paul, H Pellkofer, R Reuss, A Riedlinger, M Ringelstein, S P Rommer, K Ruprecht, S Schippling, M Schwab, M Stangel, J Stellmann, F Then-Bergh, C Trebst, H Tumani, C Veauthier, K P Wandinger, R Weissert, B Wildemann, C Wilke, A Winkelmann, L Zeltner, C Zentner, U Zettl, U Ziemann

Abstract

Neuromyelitis optica (NMO, Devic's syndrome), long considered a clinical variant of multiple sclerosis, is now regarded as a distinct disease entity. Major progress has been made in the diagnosis and treatment of NMO since aquaporin-4 antibodies (AQP4-Ab; also termed NMO-IgG) were first described in 2004. In this review, the Neuromyelitis Optica Study Group (NEMOS) summarizes recently obtained knowledge on NMO and highlights new developments in its diagnosis and treatment, based on current guidelines, the published literature and expert discussion at regular NEMOS meetings. Testing of AQP4-Ab is essential and is the most important test in the diagnostic work-up of suspected NMO, and helps to distinguish NMO from other autoimmune diseases. Furthermore, AQP4-Ab testing has expanded our knowledge of the clinical presentation of NMO spectrum disorders (NMOSD). In addition, imaging techniques, particularly magnetic resonance imaging of the brain and spinal cord, are obligatory in the diagnostic workup. It is important to note that brain lesions in NMO and NMOSD are not uncommon, do not rule out the diagnosis, and show characteristic patterns. Other imaging modalities such as optical coherence tomography are proposed as useful tools in the assessment of retinal damage. Therapy of NMO should be initiated early. Azathioprine and rituximab are suggested as first-line treatments, the latter being increasingly regarded as an established therapy with long-term efficacy and an acceptable safety profile in NMO patients. Other immunosuppressive drugs, such as methotrexate, mycophenolate mofetil and mitoxantrone, are recommended as second-line treatments. Promising new therapies are emerging in the form of anti-IL6 receptor, anti-complement or anti-AQP4-Ab biologicals.

Figures

Fig. 1
Fig. 1
Long-term therapy of NMO

References

    1. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14. doi: 10.1186/1742-2094-9-14.
    1. Trebst C, Berthele A, Jarius S, Kümpfel T, Schippling S, Wildemann B, Wilke C. Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group. Nervenarzt. 2011;82:768–777. doi: 10.1007/s00115-010-3192-4.
    1. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord. 2012;1:180–187. doi: 10.1016/j.msard.2012.06.002.
    1. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17:1019–1032. doi: 10.1111/j.1468-1331.2010.03066.x.
    1. Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;77:2128–2134. doi: 10.1212/WNL.0b013e31823dc535.
    1. Jarius S, Wildemann B. Neuromyelitis optica. Nervenarzt. 2007;78:1365–1377. doi: 10.1007/s00115-007-2262-8.
    1. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome) Neurology. 1999;53:1107–1114. doi: 10.1212/WNL.53.5.1107.
    1. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10:8. doi: 10.1186/1742-2094-10-8.
    1. Jarius S, Wildemann B. The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation. J Neurol. 2012;259:1354–1357. doi: 10.1007/s00415-011-6355-8.
    1. Jarius S, Wildemann B. “Noteomielite” accompanied by acute amaurosis (1844). An early case of neuromyelitis optica. J Neurol Sci. 2012;313:182–184. doi: 10.1016/j.jns.2011.09.025.
    1. Jarius S, Wildemann B. An early British case of neuromyelitis optica (1850) BMJ. 2012;345:e6430. doi: 10.1136/bmj.e6430.
    1. Jarius S, Wildemann B. An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS. Mult Scler. 2011;17:1384–1386. doi: 10.1177/1352458511411758.
    1. Jarius S, Wildemann B. On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. J Neurol. 2013;260:100–104. doi: 10.1007/s00415-012-6594-3.
    1. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol. 1993;34:162–168. doi: 10.1002/ana.410340211.
    1. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125:1450–1461. doi: 10.1093/brain/awf151.
    1. Lee D-H, Metz I, Berthele A, Stadelmann C, Brück W, Linker RA, Gold R, Schroeder A. Supraspinal demyelinating lesions in neuromyelitis optica display a typical astrocyte pathology. Neuropathol Appl Neurobiol. 2010;36:685–687. doi: 10.1111/j.1365-2990.2010.01105.x.
    1. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–477. doi: 10.1084/jem.20050304.
    1. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–2112. doi: 10.1016/S0140-6736(04)17551-X.
    1. Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, Vincent A, Wildemann B. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008;4:202–214.
    1. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6:383–392. doi: 10.1038/nrneurol.2010.72.
    1. Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation. 2008;5:22. doi: 10.1186/1742-2094-5-22.
    1. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009;66:617–629. doi: 10.1002/ana.21802.
    1. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66:630–643. doi: 10.1002/ana.21837.
    1. Ratelade J, Bennett JL, Verkman AS. Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS One. 2011;6:e27412. doi: 10.1371/journal.pone.0027412.
    1. Mader S, Lutterotti A, Di Pauli F, et al. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One. 2010;5:e10455. doi: 10.1371/journal.pone.0010455.
    1. Nelson PA, Khodadoust M, Prodhomme T, Spencer C, Patarroyo JC, Varrin-Doyer M, Ho JD, Stroud RM, Zamvil SS. Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. PLoS One. 2010;5:e15050. doi: 10.1371/journal.pone.0015050.
    1. Kalluri SR, Rothhammer V, Staszewski O, Srivastava R, Petermann F, Prinz M, Hemmer B, Korn T. Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. PLoS One. 2011;6:e16083. doi: 10.1371/journal.pone.0016083.
    1. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–1489. doi: 10.1212/01.wnl.0000216139.44259.74.
    1. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008;14:1157–1174. doi: 10.1177/1352458508096878.
    1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–815. doi: 10.1016/S1474-4422(07)70216-8.
    1. Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol. 2009;256:1891–1898. doi: 10.1007/s00415-009-5171-x.
    1. Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, Das K, Boggild M (2013) The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol 260:2134–2137
    1. Asgari N, Lillevang ST, Skejoe HPB, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76:1589–1595. doi: 10.1212/WNL.0b013e3182190f74.
    1. Wingerchuk DM. Neuromyelitis optica: effect of gender. J Neurol Sci. 2009;286:18–23. doi: 10.1016/j.jns.2009.08.045.
    1. Barbieri F, Buscaino GA. Neuromyelitis optica in the elderly. Acta Neurol (Napoli) 1989;11:247–251.
    1. Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, Weinshenker BG, Lucchinetti CF, Pittock SJ. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology. 2008;70:344–352. doi: 10.1212/01.wnl.0000284600.80782.d5.
    1. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology. 2008;71:93–100. doi: 10.1212/01.wnl.0000314832.24682.c6.
    1. Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics. 2008;122:e1039–e1047. doi: 10.1542/peds.2007-2758.
    1. Bergamaschi R, Jarius S, Robotti M, Pichiecchio A, Wildemann B, Meola G. Two cases of benign neuromyelitis optica in patients with celiac disease. J Neurol. 2009;256:2097–2099. doi: 10.1007/s00415-009-5288-y.
    1. Jarius S, Jacob S, Waters P, Jacob A, Littleton E, Vincent A. Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4. J Neurol Neurosurg Psychiatr. 2008;79:1084. doi: 10.1136/jnnp.2007.143263.
    1. Kay CSK, Scola RH, Lorenzoni PJ, Jarius S, Arruda WO, Werneck LC. NMO-IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy. J Neurol Sci. 2008;275:148–150. doi: 10.1016/j.jns.2008.06.038.
    1. McKeon A, Lennon VA, Jacob A, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve. 2009;39:87–90. doi: 10.1002/mus.21197.
    1. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zéphir H, Moder K, Weinshenker BG. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65:78–83.
    1. Wandinger K-P, Stangel M, Witte T, Venables P, Charles P, Jarius S, Wildemann B, Probst C, Iking-Konert C, Schneider M. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren’s syndrome. Arthritis Rheum. 2010;62:1198–1200. doi: 10.1002/art.27337.
    1. Jarius S, Jacobi C, de Seze J, et al. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler. 2011;17:1067–1073. doi: 10.1177/1352458511403958.
    1. Závada J, Nytrová P, Wandinger KP, Jarius S, Svobodová R, Probst C, Peterová V, Tegzová D, Pavelka K, Vencovský J. Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. Rheumatol Int. 2013;33:259–263. doi: 10.1007/s00296-011-2176-4.
    1. Jarius S, Paul F, Franciotta D, et al. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler. 2012;18:1135–1143. doi: 10.1177/1352458511431728.
    1. Nagaishi A, Takagi M, Umemura A, Tanaka M, Kitagawa Y, Matsui M, Nishizawa M, Sakimura K, Tanaka K. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatr. 2011;82:1360–1364. doi: 10.1136/jnnp-2011-300403.
    1. Kister I, Gulati S, Boz C, Bergamaschi R, Piccolo G, Piccolo G, Oger J, Swerdlow ML. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol. 2006;63:851–856. doi: 10.1001/archneur.63.6.851.
    1. Gotkine M, Fellig Y, Abramsky O. Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology. 2006;67:881–883. doi: 10.1212/01.wnl.0000234142.41728.a0.
    1. Vaknin-Dembinsky A, Abramsky O, Petrou P, Ben-Hur T, Gotkine M, Brill L, Brenner T, Argov Z, Karussis D. Myasthenia gravis-associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle? Arch Neurol. 2011;68:1557–1561. doi: 10.1001/archneurol.2011.200.
    1. Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012;18:5–10. doi: 10.1177/1352458511431077.
    1. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135:1834–1849. doi: 10.1093/brain/aws109.
    1. Fragoso YD, Adoni T, Bichuetti DB, Brooks JBB, Ferreira MLB, Oliveira EML, Oliveira CLS, Ribeiro SBF, Silva AE, Siquineli F. Neuromyelitis optica and pregnancy. J Neurol. 2013;260:2614–2619. doi: 10.1007/s00415-013-7031-y.
    1. Bourre B, Marignier R, Zéphir H, et al. Neuromyelitis optica and pregnancy. Neurology. 2012;78:875–879. doi: 10.1212/WNL.0b013e31824c466f.
    1. Paty DW, Oger JJ, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, Eisen KA, Purves SJ, Low MD, Brandejs V. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 1988;38:180–185. doi: 10.1212/WNL.38.2.180.
    1. Lu Z, Zhang B, Qiu W, Kang Z, Shen L, Long Y, Huang J, Hu X. Comparative brain stem lesions on MRI of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. PLoS One. 2011;6:e22766. doi: 10.1371/journal.pone.0022766.
    1. Apiwattanakul M, Popescu BF, Matiello M, Weinshenker BG, Lucchinetti CF, Lennon VA, McKeon A, Carpenter AF, Miller GM, Pittock SJ. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol. 2010;68:757–761. doi: 10.1002/ana.22121.
    1. Popescu BFG, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011;76:1229–1237. doi: 10.1212/WNL.0b013e318214332c.
    1. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65:1479–1482. doi: 10.1212/01.wnl.0000183151.19351.82.
    1. Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, Fujihara K, Tobita M, Itoyama Y. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatr. 2008;79:1075–1078. doi: 10.1136/jnnp.2008.145391.
    1. Kanbayashi T, Shimohata T, Nakashima I, Yaguchi H, Yabe I, Nishizawa M, Shimizu T, Nishino S. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol. 2009;66:1563–1566. doi: 10.1001/archneurol.2009.264.
    1. Suzuki K, Nakamura T, Hashimoto K, Miyamoto M, Komagamine T, Nagashima T, Izawa N, Kanbayashi T, Takahashi T, Hirata K. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch Neurol. 2012;69:1355–1359.
    1. Magaña SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, Shuster E, Kantarci OH, Lucchinetti CF, Weinshenker BG. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009;72:712–717. doi: 10.1212/.
    1. Schmidt F, Önder G, Jarius S, Wildemann B, Ruprecht K, Paul F, Harms L (2013) Olfactory dysfunction in patients with neuromyelitis optica. Multiple Sclerosis International: ID 654501
    1. Saadoun S, Waters P, Leite MI, Bennett JL, Vincent A, Papadopoulos MC. Neuromyelitis optica IgG causes placental inflammation and fetal death. J Immunol. 2013;191:2999–3005. doi: 10.4049/jimmunol.1301483.
    1. Reuss R, Rommer PS, Brück W, et al. A woman with acute myelopathy in pregnancy: case outcome. BMJ. 2009;339:b4026. doi: 10.1136/bmj.b4026.
    1. Reuss R, Rommer P, Brück W, Jarius S, Bolz M, Zettl UK (2010) Anti-AQP4 ab might be relevant in pregnancy. BMJ reply
    1. Cosgrove J, Alli S, Ramadan H, Ford HL. Myocarditis and diffuse skeletal muscle oedema: new features of neuromyelitis optica spectrum disorder? A case report. Mult Scler. 2013
    1. Deguchi S, Deguchi K, Sato K, et al. HyperCKemia related to the initial and recurrent attacks of neuromyelitis optica. Intern Med. 2012;51:2617–2620. doi: 10.2169/internalmedicine.51.7898.
    1. Di Filippo M, Franciotta D, Massa R, et al. Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. Neurology. 2012;79:1182–1184. doi: 10.1212/WNL.0b013e3182698d39.
    1. Suzuki N, Takahashi T, Aoki M, et al. Neuromyelitis optica preceded by hyperCKemia episode. Neurology. 2010;74:1543–1545. doi: 10.1212/WNL.0b013e3181dd445b.
    1. Jarius S, Lauda F, Wildemann B, Tumani H. Steroid-responsive hearing impairment in NMO-IgG/aquaporin-4-antibody-positive neuromyelitis optica. J Neurol. 2013;260:663–664. doi: 10.1007/s00415-012-6755-4.
    1. Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010;298:158–162. doi: 10.1016/j.jns.2010.07.011.
    1. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70:2197–2200. doi: 10.1212/01.wnl.0000303817.82134.da.
    1. Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatr. 2010;81:109–111. doi: 10.1136/jnnp.2008.146894.
    1. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59:566–569. doi: 10.1002/ana.20770.
    1. Kim S-M, Go MJ, Sung J-J, Park KS, Lee K-W. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol. 2012;69:1026–1031.
    1. Kanamori Y, Nakashima I, Takai Y, Nishiyama S, Kuroda H, Takahashi T, Kanaoka-Suzuki C, Misu T, Fujihara K, Itoyama Y. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology. 2011;77:652–658. doi: 10.1212/WNL.0b013e318229e694.
    1. Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol. 2012;69:1482–1487. doi: 10.1001/archneurol.2012.768.
    1. Jarius S, Paul F, Ruprecht K, Wildemann B. Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol. 2012;259:2743–2745. doi: 10.1007/s00415-012-6677-1.
    1. Jarius S, Wandinger KP, Borowski K, Stoecker W, Wildemann B. Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg. 2012;114:331–335. doi: 10.1016/j.clineuro.2011.10.048.
    1. Jaiser SR, Winston GP. Copper deficiency myelopathy. J Neurol. 2010;257:869–881. doi: 10.1007/s00415-010-5511-x.
    1. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8:184. doi: 10.1186/1742-2094-8-184.
    1. Rostasy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol. 2012;69:752–756. doi: 10.1001/archneurol.2011.2956.
    1. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Palace J, Vincent A. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79:1273–1277. doi: 10.1212/WNL.0b013e31826aac4e.
    1. Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013;9:455–461. doi: 10.1038/nrneurol.2013.118.
    1. Waters P, Jarius S, Littleton E, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 2008;65:913–919. doi: 10.1001/archneur.65.7.913.
    1. Hayakawa S, Mori M, Okuta A, et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol. 2008;196:181–187. doi: 10.1016/j.jneuroim.2008.03.009.
    1. Jarius S, Franciotta D, Bergamaschi R, Wright H, Littleton E, Palace J, Hohlfeld R, Vincent A. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology. 2007;68:1076–1077. doi: 10.1212/.
    1. Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W, Wandinger KP. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci. 2010;291:52–56. doi: 10.1016/j.jns.2010.01.002.
    1. Kalluri SR, Illes Z, Srivastava R, Cree B, Menge T, Bennett JL, Berthele A, Hemmer B. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol. 2010;67:1201–1208. doi: 10.1001/archneurol.2010.269.
    1. Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007;4:e133. doi: 10.1371/journal.pmed.0040133.
    1. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Ishii N, Itoyama Y. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med. 2006;210:307–313. doi: 10.1620/tjem.210.307.
    1. Jarius S, Franciotta D, Paul F, Bergamaschi R, Rommer PS, Ruprecht K, Ringelstein M, Aktas O, Kristoferitsch W, Wildemann B. Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci. 2012;320:32–37. doi: 10.1016/j.jns.2012.06.002.
    1. Kim W, Lee J-E, Li XF, Kim S-H, Han B-G, Lee BI, Kim JK, Choi K, Kim HJ. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler. 2012;18:578–586. doi: 10.1177/1352458511424590.
    1. Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 2013;23:661–683. doi: 10.1111/bpa.12084.
    1. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130:1235–1243. doi: 10.1093/brain/awm062.
    1. Ketelslegers IA, Modderman PW, Vennegoor A, Killestein J, Hamann D, Hintzen RQ. Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. Mult Scler. 2011;17:1527–1530. doi: 10.1177/1352458511412995.
    1. Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, Lang W, Reindl M, Vincent A, Kristoferitsch W. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131:3072–3080. doi: 10.1093/brain/awn240.
    1. Heerlein K, Jarius S, Jacobi C, Rohde S, Storch-Hagenlocher B, Wildemann B. Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella zoster infection. J Neurol Sci. 2009;276:184–186. doi: 10.1016/j.jns.2008.08.015.
    1. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76:1310–1315. doi: 10.1212/WNL.0b013e3182152881.
    1. Jarius S, Franciotta D, Bergamaschi R, Wildemann B, Wandinger K-P. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med. 2010;48:659–663. doi: 10.1515/CCLM.2010.127.
    1. Jarius S, Franciotta D, Paul F, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation. 2010;7:52. doi: 10.1186/1742-2094-7-52.
    1. Klawiter EC, Alvarez E, 3rd, Xu J, Paciorkowski AR, Zhu L, Parks BJ, Cross AH, Naismith RT. NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology. 2009;72:1101–1103. doi: 10.1212/01.wnl.0000345066.57745.50.
    1. Jarius S, Wildemann B. Effect of storage conditions and freeze/thaw cycles on aquaporin-4 antibody (NMO-IgG) serum levels. Clin Chem Lab Med. 2011;49:2121–2122. doi: 10.1515/CCLM.2011.717.
    1. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78:665–671. doi: 10.1212/WNL.0b013e318248dec1.
    1. De Seze J, Stojkovic T, Ferriby D, Gauvrit J-Y, Montagne C, Mounier-Vehier F, Verier A, Pruvo J-P, Hache J-C, Vermersch P. Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci. 2002;197:57–61. doi: 10.1016/S0022-510X(02)00043-6.
    1. Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica. J Neurol. 2004;251:47–52. doi: 10.1007/s00415-004-0271-0.
    1. O’Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EJ, McDonald WI, Miller DH. Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatr. 1996;60:382–387. doi: 10.1136/jnnp.60.4.382.
    1. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306:82–90. doi: 10.1016/j.jns.2011.03.038.
    1. Lepur D, Peterković V, Kalabrić-Lepur N. Neuromyelitis optica with CSF examination mimicking bacterial meningomyelitis. Neurol Sci. 2009;30:51–54. doi: 10.1007/s10072-008-0002-x.
    1. Jarius S, Wildemann B (2013) Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: A potential link. Med Hypotheses. doi:10.1016/j.mehy.2013.10.011
    1. Bergamaschi R, Tonietti S, Franciotta D, Candeloro E, Tavazzi E, Piccolo G, Romani A, Cosi V. Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler. 2004;10:2–4. doi: 10.1191/1352458504ms988oa.
    1. Jarius S, Franciotta D, Bergamaschi R, et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatr. 2008;79:1134–1136. doi: 10.1136/jnnp.2007.133330.
    1. Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, Taniguchi J, Kuwabara S. Cytokine and chemokine profiles in neuromyelitis optica: signifiance of interleukin-6. Mult Scler. 2010;16:1443–1452. doi: 10.1177/1352458510379247.
    1. Içöz S, Tüzün E, Kürtüncü M, Durmuş H, Mutlu M, Eraksoy M, Akman-Demir G. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci. 2010;120:71–75. doi: 10.3109/00207450903428970.
    1. Wang H, Wang K, Zhong X, Dai Y, Qiu W, Wu A, Hu X. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation. 2012;19:304–308. doi: 10.1159/000339302.
    1. Storoni M, Petzold A, Plant GT. The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis. PLoS One. 2011;6:e23489. doi: 10.1371/journal.pone.0023489.
    1. Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain. 2002;125:1462–1473. doi: 10.1093/brain/awf165.
    1. Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatr. 2009;80:575–577. doi: 10.1136/jnnp.2008.150698.
    1. Takano R, Misu T, Takahashi T, Izumiyama M, Fujihara K, Itoyama Y. A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med. 2008;215:55–59. doi: 10.1620/tjem.215.55.
    1. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2010;75:208–216. doi: 10.1212/WNL.0b013e3181e2414b.
    1. Uzawa A, Mori M, Sawai S, Masuda S, Muto M, Uchida T, Ito S, Nomura F, Kuwabara S. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta. 2013;421:181–183. doi: 10.1016/j.cca.2013.03.020.
    1. Ringelstein M, Kleiter I, Ayzenberg I, et al. Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler. 2013
    1. Neto SP, Alvarenga RMP, Vasconcelos CCF, Alvarenga MP, Pinto LC, Pinto VLR. Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica. Mult Scler. 2013;19:173–178. doi: 10.1177/1352458512447597.
    1. Filippi M, Rocca MA. MR imaging of Devic’s neuromyelitis optica. Neurol Sci. 2004;25(Suppl 4):S371–S373. doi: 10.1007/s10072-004-0344-y.
    1. Lim BC, Hwang H, Kim KJ, Hwang YS, Cheon J-E, Kim I-O, Kim HJ, Chae J-H. Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis optica. Mult Scler. 2011;17:67–73. doi: 10.1177/1352458510382685.
    1. Krampla W, Aboul-Enein F, Jecel J, Lang W, Fertl E, Hruby W, Kristoferitsch W. Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol. 2009;19:2535–2543. doi: 10.1007/s00330-009-1425-3.
    1. Ringelstein M, Metz I, Ruprecht K, Koch A, Rappold J, Ingwersen J, Mathys C, Jarius S, Bruck W, Hartung HP, Paul F, Aktas O (2013) Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Mult Scler. doi:10.1177/1352458513510981
    1. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390–396. doi: 10.1001/archneur.63.3.390.
    1. Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013;80:1330–1337. doi: 10.1212/WNL.0b013e3182887957.
    1. Sinnecker T, Dörr J, Pfueller CF, Harms L, Ruprecht K, Jarius S, Brück W, Niendorf T, Wuerfel J, Paul F. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology. 2012;79:708–714. doi: 10.1212/WNL.0b013e3182648bc8.
    1. Kister I, Herbert J, Zhou Y, Ge Y. Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica. Mult Scler Int. 2013;2013:398259.
    1. Nakamura M, Misu T, Fujihara K, Miyazawa I, Nakashima I, Takahashi T, Watanabe S, Itoyama Y. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler. 2009;15:695–700. doi: 10.1177/1352458509103301.
    1. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006;63:964–968. doi: 10.1001/archneur.63.7.964.
    1. Nakajima H, Fujiki Y, Ito T, Kitaoka H, Takahashi T. Anti-aquaporin-4 antibody-positive neuromyelitis optica presenting with syndrome of inappropriate antidiuretic hormone secretion as an initial manifestation. Case Rep Neurol. 2011;3:263–267. doi: 10.1159/000334129.
    1. Nakashima I, Fujihara K, Miyazawa I, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatr. 2006;77:1073–1075. doi: 10.1136/jnnp.2005.080390.
    1. Poppe AY, Lapierre Y, Melançon D, Lowden D, Wardell L, Fullerton LM, Bar-Or A. Neuromyelitis optica with hypothalamic involvement. Mult Scler. 2005;11:617–621. doi: 10.1191/1352458505ms1200cr.
    1. Banker P, Sonni S, Kister I, Loh JP, Lui YW. Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Scler. 2012;18:1050–1053. doi: 10.1177/1352458511431730.
    1. Kim W, Park MS, Lee SH, Kim S-H, Jung IJ, Takahashi T, Misu T, Fujihara K, Kim HJ. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler. 2010;16:1229–1236. doi: 10.1177/1352458510376640.
    1. Kim W, Kim S-H, Huh S-Y, Kim HJ. Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int. 2012;2012:735486.
    1. Bock M, Brandt AU, Dörr J, Pfueller CF, Ohlraun S, Zipp F, Paul F. Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study. Mult Scler. 2010;16:893–896. doi: 10.1177/1352458510365156.
    1. Oberwahrenbrock T, Schippling S, Ringelstein M, et al. Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int. 2012;2012:530305.
    1. Brandt AU, Oberwahrenbrock T, Ringelstein M, Young KL, Tiede M, Hartung HP, Martin R, Aktas O, Paul F, Schippling S. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain. 2011;134:e193. doi: 10.1093/brain/awr095.
    1. Stricker S, Oberwahrenbrock T, Zimmermann H, Schroeter J, Endres M, Brandt AU, Paul F. Temporal retinal nerve fiber loss in patients with spinocerebellar ataxia type 1. PLoS One. 2011;6:e23024. doi: 10.1371/journal.pone.0023024.
    1. Zimmermann H, Freing A, Kaufhold F, et al. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Mult Scler. 2013;19:443–450. doi: 10.1177/1352458512457844.
    1. Dörr J, Wernecke KD, Bock M, Gaede G, Wuerfel JT, Pfueller CF, Bellmann-Strobl J, Freing A, Brandt AU, Friedemann P. Association of retinal and macular damage with brain atrophy in multiple sclerosis. PLoS One. 2011;6:e18132. doi: 10.1371/journal.pone.0018132.
    1. Albrecht P, Müller A-K, Südmeyer M, et al. Optical coherence tomography in parkinsonian syndromes. PLoS One. 2012;7:e34891. doi: 10.1371/journal.pone.0034891.
    1. Oberwahrenbrock T, Ringelstein M, Jentschke S, et al. Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler. 2013
    1. Pfueller CF, Paul F. Imaging the visual pathway in neuromyelitis optica. Mult Scler Int. 2011;2011:869814.
    1. Bichuetti DB, de Camargo AS, Falcão AB, Gonçalves FF, Tavares IM, de Oliveira EML. The retinal nerve fiber layer of patients with neuromyelitis optica and chronic relapsing optic neuritis is more severely damaged than patients with multiple sclerosis. J Neuroophthalmol. 2013;33:220–224. doi: 10.1097/WNO.0b013e31829f39f1.
    1. De Seze J, Blanc F, Jeanjean L, et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol. 2008;65:920–923.
    1. Naismith RT, Tutlam NT, Xu J, Klawiter EC, Shepherd J, Trinkaus K, Song S-K, Cross AH. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology. 2009;72:1077–1082. doi: 10.1212/01.wnl.0000345042.53843.d5.
    1. Ratchford JN, Quigg ME, Conger A, Frohman T, Frohman E, Balcer LJ, Calabresi PA, Kerr DA. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology. 2009;73:302–308. doi: 10.1212/WNL.0b013e3181af78b8.
    1. Green AJ, Cree BAC. Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatr. 2009;80:1002–1005. doi: 10.1136/jnnp.2008.166207.
    1. Gelfand JM, Cree BA, Nolan R, Arnow S, Green AJ (2013) Microcystic inner nuclear layer abnormalities and neuromyelitis optica. JAMA Neurol pp 1–5
    1. Sotirchos ES, Saidha S, Byraiah G, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology. 2013;80:1406–1414. doi: 10.1212/WNL.0b013e31828c2f7a.
    1. Bouyon M, Collongues N, Zéphir H, et al. Longitudinal follow-up of vision in a neuromyelitis optica cohort. Mult Scler. 2013;19:1320–1322. doi: 10.1177/1352458513476562.
    1. Schneider E, Zimmermann H, Oberwahrenbrock T et al (2013) Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS One p e66151
    1. De Sa JCC, Airas L, Bartholome E, et al. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord. 2011;4:139–168. doi: 10.1177/1756285611403646.
    1. Samkoff LM, Goodman AD. Symptomatic management in multiple sclerosis. Neurol Clin. 2011;29:449–463. doi: 10.1016/j.ncl.2011.01.008.
    1. Chang K-H, Lyu R-K, Chen C-M, Wu Y-R, Chang H-S, Huang C-C, Kuo H-C, Chu C-C, Hsu W-C, Ro L-S. Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies. Mult Scler. 2013;19:299–307. doi: 10.1177/1352458512451659.
    1. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol. 2008;10:55–66. doi: 10.1007/s11940-008-0007-z.
    1. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002;58:143–146. doi: 10.1212/WNL.58.1.143.
    1. Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler. 2009;15:487–492. doi: 10.1177/1352458508100837.
    1. Roesner S, Appel R, Gbadamosi J, Martin R, Heesen C. Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand. 2012;126:103–108. doi: 10.1111/j.1600-0404.2011.01612.x.
    1. Bonnan M, Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int. 2012;2012:787630.
    1. Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol. 2012;130:858–862. doi: 10.1001/archophthalmol.2012.1126.
    1. Magaña SM, Keegan BM, Weinshenker BG, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011;68:870–878. doi: 10.1001/archneurol.2011.34.
    1. Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878–886. doi: 10.1002/1531-8249(199912)46:6<878::AID-ANA10>;2-Q.
    1. Nakashima I, Takahashi T, Nishiyama S, Kasahara S, Suzuki C, Misu T, Itoyama Y, Fuijihara K (2009) Plasma Exchange for Neuromyelitis Optica with Aquaporin-4 Antibody. Neurology 72:A187
    1. Llufriu S, Castillo J, Blanco Y, et al. Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology. 2009;73:949–953. doi: 10.1212/WNL.0b013e3181b879be.
    1. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, Itoyama Y. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007;13:128–132. doi: 10.1177/1352458506071174.
    1. Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2013
    1. Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DA. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology. 2007;68:1614–1617. doi: 10.1212/01.wnl.0000260970.63493.c8.
    1. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77:659–666. doi: 10.1212/WNL.0b013e31822a2780.
    1. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de Souza N, Gabbai AA. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol. 2010;67:1131–1136. doi: 10.1001/archneurol.2010.203.
    1. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, Itoyama Y. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007;13:968–974. doi: 10.1177/1352458507077189.
    1. Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics. 2010;11:177–188. doi: 10.2217/pgs.09.155.
    1. Cree BAC, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64:1270–1272. doi: 10.1212/01.WNL.0000159399.81861.D5.
    1. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65:1443–1448. doi: 10.1001/archneur.65.11.noc80069.
    1. Kim S-H, Kim W, Li XF, Jung I-J, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68:1412–1420. doi: 10.1001/archneurol.2011.154.
    1. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17:1225–1230. doi: 10.1177/1352458511404586.
    1. Kim S-H, Huh S-Y, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013
    1. Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson N, Frohman E. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler. 2012;18:1022–1026. doi: 10.1177/1352458511432896.
    1. Yang C-S, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology. 2013;81:710–713. doi: 10.1212/WNL.0b013e3182a1aac7.
    1. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66:1128–1133. doi: 10.1001/archneurol.2009.175.
    1. Neff RT, Hurst FP, Falta EM, Bohen EM, Lentine KL, Dharnidharka VR, Agodoa LY, Jindal RM, Yuan CM, Abbott KC. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation. 2008;86:1474–1478. doi: 10.1097/TP.0b013e31818b62c8.
    1. Bakker J, Metz L. Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG) Can J Neurol Sci. 2004;31:265–267.
    1. Okada K, Tsuji S, Tanaka K. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med. 2007;46:1671–1672. doi: 10.2169/internalmedicine.46.0217.
    1. Magraner MJ, Coret F, Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia. 2012;28:65–72. doi: 10.1016/j.nrl.2012.03.014.
    1. Kim S-H, Kim W, Park MS, Sohn EH, Li XF, Kim HJ. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol. 2011;68:473–479. doi: 10.1001/archneurol.2010.322.
    1. Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D, Aegis of French National Observatory of Multiple Sclerosis Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatr. 2013;84:511–516. doi: 10.1136/jnnp-2012-303121.
    1. Dörr J, Bitsch A, Schmailzl KJG, et al. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology. 2009;73:991–993. doi: 10.1212/WNL.0b013e3181b878f6.
    1. Stroet A, Hemmelmann C, Starck M, et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord. 2012;5:75–79. doi: 10.1177/1756285611433318.
    1. Martinelli V, Cocco E, Capra R, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology. 2011;77:1887–1895. doi: 10.1212/WNL.0b013e318238ee00.
    1. Bonnet F, Mercié P, Morlat P, et al. Devic’s neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus. Lupus. 1999;8:244–247. doi: 10.1191/096120399678847696.
    1. Jacobi C, Stingele K, Kretz R, Hartmann M, Storch-Hagenlocher B, Breitbart A, Wildemann B. Neuromyelitis optica (Devic’s syndrome) as first manifestation of systemic lupus erythematosus. Lupus. 2006;15:107–109. doi: 10.1191/0961203306lu2265cr.
    1. Mok CC, To CH, Mak A, Poon WL. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol. 2008;35:172–174.
    1. Yaguchi H, Sakushima K, Takahashi I, et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med. 2013;52:969–972. doi: 10.2169/internalmedicine.52.7885.
    1. Bichuetti DB, Oliveira EML, Boulos F de C, Gabbai AA (2012) Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol 69:938–939
    1. Minagar A, Sheremara W. Treatment of Devic’s disease with methotrexate and prednisone. Int J MS Care. 2000;2:39–43.
    1. Papeix C, Vidal J-S, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007;13:256–259. doi: 10.1177/1352458506070732.
    1. Shimizu J, Hatanaka Y, Hasegawa M, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75:1423–1427. doi: 10.1212/WNL.0b013e3181f8832e.
    1. Palace J, Leite MI, Nairne A, Vincent A. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010;67:1016–1017. doi: 10.1001/archneurol.2010.188.
    1. Kim S-H, Kim W, Li XF, Jung I-J, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler. 2012;18:1480–1483. doi: 10.1177/1352458512439439.
    1. Uzawa A, Mori M, Hayakawa S, Masuda S, Kuwabara S. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol. 2010;17:672–676. doi: 10.1111/j.1468-1331.2009.02897.x.
    1. Gartzen K, Limmroth V, Putzki N. Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. Eur J Neurol. 2007;14:e12–e13. doi: 10.1111/j.1468-1331.2007.01807.x.
    1. Bergamaschi R, Uggetti C, Tonietti S, Egitto MG, Cosi V. A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol. 2003;250:359–361. doi: 10.1007/s00415-003-0979-2.
    1. Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, Jacob A, Leite MI, Palace J. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013;84:918–921. doi: 10.1136/jnnp-2012-304774.
    1. Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung H-P, Paul F, Aktas O. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69:239–245. doi: 10.1001/archneurol.2011.216.
    1. Barnett MH, Prineas JW, Buckland ME, Parratt JDE, Pollard JD. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012;18:108–112. doi: 10.1177/1352458511421185.
    1. Jacob A, Hutchinson M, Elsone L, Kelly S, Ali R, Saukans I, Tubridy N, Boggild M. Does natalizumab therapy worsen neuromyelitis optica? Neurology. 2012;79:1065–1066. doi: 10.1212/WNL.0b013e31826845fe.
    1. Min J-H, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012;18:113–115. doi: 10.1177/1352458511431973.
    1. Kageyama T, Komori M, Miyamoto K, Ozaki A, Suenaga T, Takahashi R, Kusunoki S, Matsumoto S, Kondo T. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol. 2013;260:627–634. doi: 10.1007/s00415-012-6692-2.
    1. Miyamoto K, Kusunoki S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial. 2009;13:505–508. doi: 10.1111/j.1744-9987.2009.00780.x.
    1. Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, Ogawa M, Toda T, Yamamura T. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA. 2011;108:3701–3706. doi: 10.1073/pnas.1017385108.
    1. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. 2013;23:827–831. doi: 10.3109/s10165-012-0715-9.
    1. Kieseier BC, Stüve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 2012;70:390–393. doi: 10.1001/jamaneurol.2013.668.
    1. Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, Yamamura T, Gold R. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013;70:394–397. doi: 10.1001/jamaneurol.2013.1246.
    1. Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O’Toole O, Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12:554–562. doi: 10.1016/S1474-4422(13)70076-0.
    1. Paul F. Hope for a rare disease: eculizumab in neuromyelitis optica. Lancet Neurol. 2013;12:529–531. doi: 10.1016/S1474-4422(13)70089-9.
    1. Tradtrantip L, Zhang H, Saadoun S, Phuan P-W, Lam C, Papadopoulos MC, Bennett JL, Verkman AS. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 2012;71:314–322. doi: 10.1002/ana.22657.
    1. Miyazaki K, Abe Y, Iwanari H, et al. Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4. J Neuroimmunol. 2013;260:107–116. doi: 10.1016/j.jneuroim.2013.03.003.
    1. Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol. 2012;71:323–333. doi: 10.1002/ana.22686.
    1. Zhang H, Verkman AS. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest. 2013;123:2306–2316. doi: 10.1172/JCI67554.
    1. Tradtrantip L, Asavapanumas N, Verkman AS. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol Pharmacol. 2013;83:1268–1275. doi: 10.1124/mol.113.086470.
    1. Tradtrantip L, Ratelade J, Zhang H, Verkman AS. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol. 2013;73:77–85. doi: 10.1002/ana.23741.
    1. Matiello M, Pittock SJ, Porrata L, Weinshenker BG. Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica. Arch Neurol. 2011;68:953–955. doi: 10.1001/archneurol.2011.38.
    1. Qian P, Cross AH, Naismith RT. Lack of response to monoclonal antibody therapy in neuromyelitis optica. Arch Neurol. 2011;68:1207–1209. doi: 10.1001/archneurol.2011.194.
    1. Vaknin-Dembinsky A, Brill L, Kassis I, Petrou P, Ovadia H, Ben-Hur T, Abramsky O, Karussis D. T-cell reactivity against AQP4 in neuromyelitis optica. Neurology. 2012;79:945–946. doi: 10.1212/WNL.0b013e318266fc2b.
    1. Weiner HL. Role of T cells in neuromyelitis optica. Ann Neurol. 2012;72:6–8. doi: 10.1002/ana.23669.
    1. Herges K, de Jong BA, Kolkowitz I, et al. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler. 2012;18:398–408. doi: 10.1177/1352458512440060.
    1. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11:535–544. doi: 10.1016/S1474-4422(12)70133-3.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner